Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Ovarian Cancer Maintenance Therapies Stack Up On Costs And Value

Executive Summary

With new branded immunotherapy-based double- or triple-drug combinations on the way, there is greater scrutiny of costs and efficiency.

Advertisement

Related Content

Avastin Biosimilar Battle: Amgen, Genentech File Dueling Suits
Lynparza Poised For Growth With Broad Ovarian Cancer Approval
The PARP Combo Race Is On: Clovis And Bristol Partner On Rubraca
Immuno-Oncology Outlook: Bavencio Leads PD-1/L1 Pack In Ovarian Cancer
Ovarian Cancer Drugs Will Get ICER Review As Olaparib's Maintenance Indication Looms
ASCO Data Support Roche’s Grand Plan For Non-Stop Avastin Treatment
Roche's Long View: ASCO Marks Progress In Shifting To Lengthier Treatment Duration For Avastin, Rituxan

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123281

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel